Breast Neoplasm Clinical Trial
Official title:
A Phase I/IIa Study of SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer Patients
Verified date | December 2019 |
Source | BriaCell Therapeutics Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a single arm, open label study of SV-BR-1-GM, a targeted immunotherapy for breast cancer. Eligible patients will have histological confirmation of breast cancer with recurrent and/or metastatic lesions. The treatment regimen includes a pre-treatment with low-dose cyclophosphamide 2-3 days before the inoculation; inoculation in 4 sites on the thighs and upper back; and post-treatment inoculation of Interferon-alpha-2b into the sites of inoculation ~2 and ~4 days after the inoculation. These is repeated every 2 weeks for one month (3 treatments), then monthly for up to one year. Standard tumor assessments are performed at baseline and then every 2-3 months.
Status | Completed |
Enrollment | 24 |
Est. completion date | November 22, 2018 |
Est. primary completion date | November 22, 2018 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 1. Have histological confirmation of breast cancer with recurrent and/or metastatic lesions via investigational site. - Patients with new or progressive breast cancer metastatic to brain will be eligible provided: 1. There is no need for steroids and patients have not had steroids at least 2 weeks 2. No individual tumor size is >50 mm3 3. ECOG status <3 4. Tumor is not impinging on Middle Cerebral Artery/speech-motor strip 5. If surgically debulked, must be healed from surgery and at least 3 weeks have elapsed since general anesthesia 6. Patients consent to MRI studies at 3-4 week intervals until evidence of tumor regression on at least 2 imaging studies. In no case, will the interval between MRI studies be longer than 3 months. MRI study may be introduced at any time should the patients develop new or clearly worsening symptoms and/or introduction of steroids 2. Have evidence of persistent, recurrent, or progressive disease for which there is no known or established treatment available with curative intent, after failing at least one course of community standard systemic treatment with chemotherapy (and endocrine therapy if appropriate) 3. Be 18 years of age or older and female 4. Have expected survival of at least 4 months 5. Have adequate performance status (ECOG 0-2) 6. Patients may be maintained on hormonal therapy provided there is clear evidence of tumor progression 7. Have provided written informed consent. Exclusion Criteria: 1. Concurrent or recent chemotherapy (within 3 weeks), XRT within 3 weeks, may have had immunotherapy in the past (off within 3 weeks), or general anesthesia/major surgery (within 3 weeks). Patients must have recovered from all known or expected toxicities from previous treatment and passed a treatment-free "washout" period of 3 weeks before starting this program (8 weeks for persons receiving nitrosourea or mitomycin). 2. History of clinical hypersensitivity to GM-CSF, Interferon-alpha-2b (Merck), yeast, beef, or to any components used in the preparation of the experimental vaccine. 3. BUN >30 and a creatinine >2. 4. Absolute granulocyte count < 1000; platelets <100,000. 5. Bilirubin >2.0; alkaline phosphatase >5x upper limit of normal (ULN); ALT/AST >2x ULN. 6. Proteinuria >1+ on urinalysis or >1 gm/24hr. 7. Left ventricular ejection fraction (LVEF as determined by cardiac echo or MUGA scan) below the normal limits of the institutions specific testing range. This assessment may be repeated once at the discretion of the Investigator with the approval of the Sponsor. 8. New York Heart Association stage 3 or 4 cardiac disease. 9. A pleural effusion of moderate severity or worse. 10. Any woman of childbearing potential, unless she: 1. Agrees to take measures to avoid becoming pregnant during the study and 2. Has a negative serum pregnancy test within 7 days prior to starting treatment. 11. Women who are pregnant or nursing. 12. Patients with concurrent second malignancy. Persons with previous malignancies effectively treated and not requiring treatment for >24 months are eligible, provided there is unambiguous documentation that current local recurrence or metastatic site represents recurrence of the primary breast malignancy. 13. Patients who are HIV positive (by self-report) or have clinical or laboratory features indicative of AIDS. 14. 14. Patients who require systemic steroids at a dose equivalent of >10 mg/day of prednisone. Beta-blocker therapy, while not exclusionary, is discouraged and alternatives should be sought if possible. The beta-blocker might compromise use of epinephrine for the rare possibility of anaphylaxis. Anticoagulants must be approved by the Investigator with notification of the Sponsor. 15. Patients who are on treatment for rheumatological or autoimmune disease unless approved by the Investigator in consultation with the Sponsor (e.g., as for replacement therapy for autoimmune thyroiditis or diabetes). 16. Patients with severe psychiatric (i.e. schizophrenia, bipolar, or borderline personality disorder) or other clinically progressive major medical problems, unless approved by the PI. 17. Male breast cancer patients. 18. Patients may not be on a concurrent clinical trial, unless approved by PI. |
Country | Name | City | State |
---|---|---|---|
United States | Providence Regional Medical Center | Everett | Washington |
United States | Thomas Jefferson University | Philadelphia | Pennsylvania |
United States | University of Miami/Sylvester at Plantation | Plantation | Florida |
United States | St. Joseph Heritage Healthcare | Santa Rosa | California |
United States | Cancer Center of Kansas (CCK) | Wichita | Kansas |
Lead Sponsor | Collaborator |
---|---|
BriaCell Therapeutics Corporation | Cancer Insight, LLC |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Immune Responses to Vaccine | To assess immune responses to SV-BR-1-GM, and to recall antigens, if any, as measured by DTH skin tests and/or other immunological tests | Through study completion, an average of 1 year | |
Other | Quality of Life Using the SF-36 Health Survey | To measure the quality of life (QOL) of participants using the SF-36 Health Survey, which includes measures of General Health, Limitations of Activity, Physical Health Problems, Emotional Health Problems, Social Activities, Energy and Emotions. | Through study completion, an average of 1 year | |
Other | Weight | To measure changes in weight. | Through study completion, an average of 1 year | |
Other | Performance Status | To measure changes in performance status using the Eastern Cooperative Oncology Group (ECOG) scale | Through study completion, an average of 1 year | |
Other | Pain (Pain Scale) | To measure changes in pain using a scale from None to Very Mild to Mild to Moderate to Severe to Very Severe | Through study completion, an average of 1 year | |
Primary | Number of Patients With Treatment Emergent Adverse Events Occurring in Two or More Patients [Safety] | To evaluate the number of patients with toxicity events while on SV-BR-1-GM, as defined by the Common Terminology Criteria for Adverse Events (CTCAE) | Through study completion, an average of 1 year | |
Secondary | Duration of Treatment Emergent Adverse Events [Safety] | To evaluate the duration of toxicity events while on SV-BR-1-GM, as defined by CTCAE | Through study completion, an average of 1 year | |
Secondary | Number of Participants With an Adverse Event Related to SV-BR-1-GM Administration [Safety] | To evaluate the number of participants with an adverse event related to SV-BR-1-GM administration, as defined by CTCAE | Through study completion, an average of 1 year | |
Secondary | Objective Tumor Response Rate | Objective response rate (ORR), defined as complete response (CR) or partial response (PR) per response evaluation criteria in solid tumors (RECIST) and immune-related RECIST (iRECIST) criteria. | Through study completion, an average of 1 year | |
Secondary | Rate of Non-progression of Tumors | Non-progressive rate, defined as CR, PR or stable disease (SD) per RECIST and iRECIST criteria | Through study completion, an average of 1 year | |
Secondary | Durability of Tumor Response | Durability of response, as defined as complete response (disappearance of all tumors), partial response (30% or greater reduction in the sum of diameters of target lesions (tumors) with stable disease in non-target lesions) or stable disease (less than 20% increase in the sum of diameters of target lesions with no new lesions appearing) by evaluating those patients eligible to complete the optional treatments from 9-12 months | Through study completion, an average of 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03273426 -
Prediction of pCR by Preoperative Biopsy in Breast Cancer With cCR After Neoadjuvant Chemotherapy.
|
N/A | |
Recruiting |
NCT04583124 -
Adjusting the Dose of Therapeutic Exercise to Prevent Neurotoxicity Due to Anticancer Treatment (ATENTO)
|
N/A | |
Active, not recruiting |
NCT04489173 -
TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer
|
Phase 2 | |
Recruiting |
NCT02913573 -
Effect of Pectoral Nerve Block on Post-op Pain in Patients Undergoing Mastectomy and Immediate Reconstruction
|
Phase 2 | |
Completed |
NCT03124095 -
Combined Training Intervention for Women Who Underwent Primary Treatment for Breast Cancer
|
N/A | |
Terminated |
NCT00251095 -
Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer
|
Phase 3 | |
Completed |
NCT05576545 -
Develop and Evaluate the Effectiveness of a Self-Care Smartphone Application on the Self-Efficacy, and Resilience Among Newly Diagnosed Breast Cancer Patients Undergoing Treatment
|
N/A | |
Active, not recruiting |
NCT03625635 -
Effect of a Clinical Nutrition Intervention Program in Breast Cancer Patients During Antineoplastic Treatment
|
N/A | |
Recruiting |
NCT04799535 -
Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring
|
||
Withdrawn |
NCT03266562 -
Estrogen Receptor Expression in Breast Cancer - Assessed With Positron Emission Mammography
|
N/A | |
Completed |
NCT00530868 -
Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
|
Phase 2 | |
Recruiting |
NCT06255808 -
Development of Assist Tool for Breast Examination Using the Principle of Ultrasonic Sensor
|
||
Completed |
NCT04640220 -
Improvement of Range of Motion in Frozen Shoulder in Breast Cancer Survivors
|
N/A | |
Completed |
NCT02970682 -
SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT02316561 -
Single Dose Ablative Radiation Treatment for Early-Stage Breast Cancer
|
N/A | |
Terminated |
NCT00638963 -
Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)
|
Phase 2 | |
Terminated |
NCT00249301 -
A Study of MLN8054 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06056414 -
Study of Anxiety After a Session of Energy Resonance by Cutaneous Stimulation
|
N/A | |
Recruiting |
NCT05427071 -
Magnetic Marker Localization for Occult Breast Cancer and Target Axillary Dissection in Node-positive Breast Cancer Post-neoadjuvant Chemotherapy
|
N/A | |
Recruiting |
NCT03740893 -
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer
|
Phase 2 |